Description
Product Usage Information
This product is the carrier free version of product #81284. All data were generated using the same antibody clone in the standard formulation which contains BSA and glycerol. This formulation is ideal for use with technologies requiring specialized or custom antibody labeling, including fluorophores, metals, lanthanides, and oligonucleotides. It is not recommended for ChIP, ChIP-seq, CUT&RUN or CUT&Tag assays. If you require a carrier free formulation for chromatin profiling, please contact us . Optimal dilutions/concentrations should be determined by the end user. BSA and Azide Free antibodies are quality control tested by size exclusion chromatography (SEC) to determine antibody integrity.
Formulation
Supplied in 1X PBS (10 mM Na 2 HPO 4 , 3 mM KCl, 2 mM KH 2 PO 4 , and 140 mM NaCl (pH 7.8)). BSA and Azide Free. For standard formulation of this product see product # 81284
Storage
Store at -20°C. This product will freeze at -20°C so it is recommended to aliquot into single-use vials to avoid multiple freeze/thaw cycles. A slight precipitate may be present and can be dissolved by gently vortexing. This will not interfere with antibody performance.
Specificity / Sensitivity
ADAR1 (E6X9R) Rabbit Monoclonal Antibody (BSA and Azide Free) recognizes endogenous levels of total ADAR1 protein.
Species Reactivity: Human, Monkey
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu419 of human ADAR1 protein.
Background
Post-transcriptional processing of RNAs, such as RNA editing, is an important mechanism by which diversity in RNA and protein is achieved that is not otherwise encoded by the genome (1,2). The most common form of RNA editing is the conversion of adenosine (A) into inosine (I) on double-stranded RNA by the adenosine deaminase acting on RNA (ADAR) family of proteins (1-3). Since inosine base pairs with cytidine, it is interpreted as a guanosine by the splicing and translational machinery, leading to alteration in the protein sequence, as well as generation of splicing isoforms (1,4-6). A-to-I editing can also influence RNA sequence recognition by RNA-binding proteins and non-coding RNA, such as miRNAs, affecting subsequent RNA processing, stability, and protein expression levels (2). ADAR1 is ubiquitously expressed with two known isoforms, ADAR1L (p150) and ADAR1S (p110), resulting from transcription using alternative promoters and start codons. ADAR1S is constitutively expressed in the nucleus, while ADAR1L is interferon-inducible and present in both the nucleus and the cytoplasm. The induction of ADAR1L in response to cellular stress and viral infection suggests a role for RNA editing in the innate immune response (1,7). In addition, ADAR1 is essential in mammalian development, particularly in hematopoiesis and suppression of interferon signaling to protect hematopoietic stem cells from destruction in fetal liver and adult bone marrow (8,9).
Alternate Names
136 kDa double-stranded RNA binding protein; 136 kDa double-stranded RNA-binding protein; ADAR; ADAR1; adenosine deaminase acting on RNA 1-A; adenosine deaminase RNA specific; adenosine deaminase, RNA-specific; AGS6; Double-stranded RNA-specific adenosine deaminase; DRADA; DSH; DSRAD; dsRNA adenosine deaminase; dsRNA adeonosine deaminase; G1P1; IFI-4; IFI4; interferon-induced protein 4; Interferon-inducible protein 4; K88DSRBP; p136
